about
A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogensIL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanismsIdentification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitorsStructure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitorsLead identification of novel and selective TYK2 inhibitors2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitorsInterleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381QInterleukin-22 mediates early host defense against attaching and effacing bacterial pathogensInterleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17.A mouse knockout library for secreted and transmembrane proteins.Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-γ for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages.Oral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans infections.Homeostatic IL-23 receptor signaling limits Th17 response through IL-22-mediated containment of commensal microbiota.IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells.IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available.Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniaeIL-27 promotes T cell-dependent colitis through multiple mechanisms.Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells.Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis.Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo.Interleukin 27R regulates CD4+ T cell phenotype and impacts protective immunity during Mycobacterium tuberculosis infection.Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection.IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lungThe biology and therapeutic potential of interleukin 27.Targeting the development and effector functions of TH17 cells.Intestinal lamina propria dendritic cells maintain T cell homeostasis but do not affect commensalism.Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31.The adaptor CARD9 is required for adaptive but not innate immunity to oral mucosal Candida albicans infections.T Cell-Derived IL-10 Impairs Host Resistance to Mycobacterium tuberculosis Infection.IL-27 Directly Enhances Germinal Center B Cell Activity and Potentiates Lupus in Sanroque Mice.Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1.A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression.Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice.
P50
Q24292402-D5275CF7-C44A-4AC0-9A98-9C8BD7C58B82Q24307492-37480FD3-65AB-47DA-ACC0-83459A696F30Q24569645-9AC8C691-942E-4A6E-8B1F-BBB6528F12BEQ27644279-00FFB9E0-41F0-47D2-9178-6C01D7DDA9A7Q27644486-F4ACBAC9-B1F4-457B-9DC2-940451B4835AQ27679110-44C34B4D-D7F4-4994-B437-A0756ADC1487Q27683098-D9CE0197-85A1-4D5A-A7F0-398B548D2F05Q27684544-25AFEEFD-57B4-47F3-B57F-1ADF80B2132BQ27684603-0404B277-20A3-4270-AD72-1D2A82979CCBQ27685240-64DEE836-8F10-4BA8-8CF1-0AE7ECCA4A02Q27685250-33824477-C33D-4B57-9898-58BB18F817C4Q28213628-2FE11042-B9E9-44CC-BF32-DCFCC625F430Q28743977-F848260E-0ADD-4832-AA3F-F311310B9100Q29617432-615453A6-D5DF-476D-9064-68C6D1609B2DQ33590409-89391626-E56F-413A-8A68-B8D5F07C4E54Q33609631-DC44DC81-04A3-478F-9BA4-DF1FA817FA36Q34222028-EE90DF92-BC49-4574-AC4C-2DAD5D3B66F1Q34230506-E2ED91CC-5291-48E2-937F-826496F5F20AQ34281233-7F25C9EE-0E5B-4732-A899-B332C9543072Q34420821-9E6AC36B-344D-4AA4-914D-CEF5A7AF9516Q34432140-3E69D046-8C37-41B8-9007-E225EA0EDA7FQ34450323-74121A84-28B1-4BD7-AE55-FAAD88D9A8FAQ34501413-65C045D8-C5D3-4AA0-9914-76B88465D78AQ34556912-E84B77A4-E886-4F0E-86FA-953A63232761Q34727652-86F99A43-47A1-428C-AFDA-B321063A6C75Q34847758-77C27FAF-3B62-42A6-B9E4-BF9E97F9DFBBQ35992186-05432D0B-E473-4B56-9D1C-28B1AF1C9153Q36228693-49238EBF-B1C4-446C-8E1C-C80DA74E17F5Q36267150-37456C7F-DCAA-4CFA-8CB0-CBBFDB05B660Q36733744-0C9F1957-337C-472B-83B0-7A39B4C4202AQ37033544-E9395EB8-F57E-4C99-9EDE-D7F681943926Q37194987-AAB1F6DF-9239-4D3A-8471-034AEF9BA8FAQ37252260-DC2B2898-17D5-4432-9B5F-AA3BD8A75976Q38328470-810512CE-A74B-429A-B984-6FA7EB951A7DQ38742184-5D0DFAAA-2453-4CBC-A4A1-89877278CCAFQ39399282-E9E2F4F1-6714-4F66-982C-A106327FA944Q41965864-0E8C913F-68B0-4221-8CB5-12C704AE611EQ41995656-08401EF0-0C2E-4B5B-B8AC-568F7D347B43Q42381249-457E4586-B5AF-4AF3-8F54-B6CDF0589162Q42620442-F2742DA7-6B79-4839-B2BA-E5F5FDA43473
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-4945-3097
@en
name
Nico Ghilardi
@ast
Nico Ghilardi
@en
Nico Ghilardi
@es
Nico Ghilardi
@fr
Nico Ghilardi
@nl
type
label
Nico Ghilardi
@ast
Nico Ghilardi
@en
Nico Ghilardi
@es
Nico Ghilardi
@fr
Nico Ghilardi
@nl
prefLabel
Nico Ghilardi
@ast
Nico Ghilardi
@en
Nico Ghilardi
@es
Nico Ghilardi
@fr
Nico Ghilardi
@nl
P106
P21
P31
P496
0000-0003-4945-3097